Home LiteratureArticle Details
PMID: 19942921 Published · ppublish English Journal Article Comment

Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?

Nature reviews. Clinical oncology ·Vol. 6 ·No. 12 ·2009-12-00 ·Pages 679-80

Choueiri TK, Atkins MB

Abstract

Sunitinib is a standard first-line therapy for patients with advanced or metastatic clear-cell renal cell carcinoma. in an expanded-access study, sunitinib has demonstrated clinical benefit with an acceptable safety profile in a population of patients that is representative of those seen in clinical practice.

MeSH Terms
Antineoplastic Agents/therapeutic use Carcinoma, Renal Cell/drug therapy Humans Indoles/therapeutic use Kidney Neoplasms/drug therapy Prognosis Pyrroles/therapeutic use Sunitinib
Chemicals
Antineoplastic Agents Indoles Pyrroles Sunitinib
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Choueiri Toni K
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Atkins Michael B
References (7)
7 references, click to expand
  1. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
    J Natl Cancer Inst. 2008 Oct 15;100(20):1454-63 PMID: 18840822
  2. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
    Lancet Oncol. 2009 Aug;10(8):757-63 PMID: 19615940
  3. Optimizing recent advances in metastatic renal cell carcinoma.
    Curr Oncol Rep. 2009 May;11(3):218-26 PMID: 19336014
  4. Treatment selection for patients with metastatic renal cell carcinoma.
    Cancer. 2009 May 15;115(10 Suppl):2327-33 PMID: 19402069
  5. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
    N Engl J Med. 2007 Jan 11;356(2):115-24 PMID: 17215529
  6. Sunitinib in patients with metastatic renal cell carcinoma.
    JAMA. 2006 Jun 7;295(21):2516-24 PMID: 16757724
  7. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
    J Clin Oncol. 2002 Jan 1;20(1):289-96 PMID: 11773181
Article Info
Journal
Nature reviews. Clinical oncology
Abbr.
Nat Rev Clin Oncol
ISSN
1759-4782
DOI
10.1038/nrclinonc.2009.170
Published
2009-12-00
Pages
679-80
Language
English
Region
England
NLM ID
101500077
Subset
IM
Corrections
CommentOn
PMID: 19615940
External Links
PubMed source DOI: 10.1038/nrclinonc.2009.170 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2